Their ability to promote satiety while minimizing caloric intake could be beneficial for individuals struggling with obesity or metabolic syndrome
Approval (2017) FDA News Release: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (March 08, 2024) Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation (May 17, 2025) Once-Weekly Semaglutide in Adults With Overweight or Obesity (March 2021) Oral Semaglutide Versus Subcutaneous Liraglutide And Placebo In Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial Wegovy Dosing Schedule Ozempic Dosing Schedule Rybelsus Dosing Schedule
Tambin ha trabajado como investigador principal en ensayos clnicos respaldados por Abbvie, UCB, Janssen, Bristol Myers Squibb, Lilly, Galderma, Sanofi y Novartis
Mechanistically, apigenin demonstrated neuroprotective potential by upregulating Nrf2 and HO-1, reducing oxidative stress, and promoting intestinal crypt cell proliferation while inhibiting apoptosis
Benefits: Brightening your Skin
